AGEN Agenus Inc.

-0.01  -0%
Previous Close 2.54
Open 2.52
Price To Book -1.96
Market Cap 339539596
Shares 134,205,374
Volume 605,207
Short Ratio
Av. Daily Volume 1,283,604

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 enrolment to be completed 2019.
AGEN2034 and AGEN1884
Solid tumors
Phase 1 presentation at ASCO 2018. 31% ORR.
AGEN1884 (anti-CTLA-4)
Solid cancers
Approval announced October 20, 2017.
Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
AGEN2034 (anti-PD-1)
Cervical cancer
Phase 1/2 trial initiation announced November 30, 2016.
Solid tumors - cancer
Phase 1/2 trial commenced June 2016
Solid tumors - cancer

Latest News

  1. Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?
  2. Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
  3. Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
  4. Agenus Announces Clinical Appointments
  5. 3 Top Growth Stocks to Buy Right Now
  6. Edited Transcript of AGEN earnings conference call or presentation 14-Mar-19 12:30pm GMT
  7. Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
  8. Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript
  9. Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
  10. Agenus: 4Q Earnings Snapshot
  11. Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  12. Agenus Milestone Triggers $7.5M Payment from Gilead
  13. Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
  14. The 3 Oldest Members of Biotech's Billion-Burned Club
  15. Analysis: Positioning to Benefit within Micron Technology, Caterpillar, Agenus, Fossil Group, Marathon Petroleum, and Geo Group — Research Highlights Growth, Revenue, and Consolidated Results
  16. Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare
  17. Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019
  18. Why Agenus Inc. Stock Took Flight in January
  19. Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
  20. Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?